Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

Ulta Beauty revised its guidance downward, indicating a departure from its historical EPS growth. Find out what leads to a ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Many fintech stocks stumbled in 2022 and 2023 as inflation and rising interest rates curbed consumer spending, cooled the ...

The 2021-22 incorporation ... half of 2023. But it was also overweight stocks coming into 2022, which hurt in the early stages of the bear market. The team did add value in 2020’s up-and-down ...

Regulators say Invesco felt pressure to overstate its investment support for environmental, social and governance causes for ...

The cryptocurrency sector reached a peak market value ... for Block in 2020 and 2021, although the trading feature did little to help the company's bottom line. In 2023, Block managed $2.56 ...

While potential Trump tariffs spark investor anxiety, a far more critical risk is unfolding in Asia. Are you prepared?

It has held a double digit advantage on the competition since 2020 ... 2021, DoorDash went public on the New York Stock Exchange at a $72 billion valuation. That valuation has declined considerably ...

The S&P 500's concentration in Magnificent Seven stocks has led to a rare phenomenon in 2024, and it portends big gains in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

See how we rate investing products to write unbiased product reviews. The U.S. stock market generally closes for major holidays like Memorial Day, Independence Day, and Thanksgiving. But not all ...